Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women With Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy

Next Previous
X
Search
Trial Profile

A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women With Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exemestane (Primary) ; Tamoxifen (Primary) ; Triptorelin (Primary) ; Antineoplastics
  • Indications Breast cancer; Ductal carcinoma
  • Focus Therapeutic Use
  • Acronyms PERCHE

    • Most Recent Events

    • 12 Jul 2011 Additional trial centre and locations identified as reported by European Clinical Trials Database record.
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database record).
    • 08 May 2009 Additional lead trial centre identified as reported by Australian New Zealand Clinical Trials Registry record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top